Transcode Therapeutics RNAZ Income Statement (2020-2026)

NASDAQ RNAZ
$1.78 -0.11 (-5.82%)
At close: Sep 9, 2026 · 4:00 PM EDT
Reported Financials

Transcode Therapeutics Quarterly Income Statement

Periods 25 quarters
Latest Jun 2026

Transcode Therapeutics reported net income of -$6.87M for the quarter ended Jun 2026. This income statement covers 25 quarters of results from Jun 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity)Shares Outstanding (Entity.)
0.02M0.01M0.02M0.02M0.02M0.02M0.02M0.04M0.10M0.01M0.18M0.22M0.52M0.36M4.82M0.83M0.83M0.69M0.92M1.01M
Operating items
Research & DevelopmentR&D
0.99M1.29M1.88M2.62M3.04M2.69M2.59M2.97M3.34M3.36M1.76M3.08M1.23M3.64M2.22M2.57M3.16M5.48M5.11M3.69M
Selling, General & AdministrativeSG&A
1.37M1.70M1.60M2.09M1.91M2.81M2.30M2.16M1.97M0.73M1.53M2.03M0.94M1.45M0.95M1.66M1.40M1.76M2.22M2.54M
Other Operating ExpensesOther Opex
8.79M-0.12M0.22M
Operating ExpensesOpex
2.36M2.99M3.48M4.71M4.95M5.50M4.89M5.12M5.31M4.10M3.29M5.11M2.17M5.09M3.17M4.22M4.56M16.03M17.76M6.79M
Operating IncomeOp. Inc
-2.36M-2.99M-3.48M-4.71M-4.95M-5.50M-4.89M-5.12M-5.31M-4.10M-3.29M-5.11M-2.17M-5.09M-3.17M-4.22M-4.56M-16.03M-17.76M-6.79M
EBIT
-2.36M-2.99M-3.48M-4.71M-4.95M-5.50M-4.89M-5.12M-5.31M-4.10M-3.29M-5.11M-2.17M-5.09M-3.17M-4.22M-4.56M-16.03M-17.76M-6.79M
Non-operating items
Non Operating Interest Expenses
333.000.01M0.01M0.02M0.02M0.01M0.00M0.01M0.00M114.000.01M542.00
Interest & Investment IncomeInt & Inv Inc
141.00510.00442.000.00M0.01M0.01M0.00M246.00131.00137.00168.00178.00179.00159.00146.00148.00147.000.08M0.09M0.05M
Other Non Operating IncomeOther Non Op Inc.
-0.06M-0.07M-0.16M0.23M-0.03M-0.05M-0.03M-0.01M-0.02M-0.04M
Non Operating IncomeNon Op. Inc.
0.03M0.19M0.01M0.04M0.66M0.36M0.07M0.78M0.01M0.01M-0.04M-0.08M-0.16M-0.82M-8.91M-0.06M-0.29M2.81M0.20M0.04M
Net income details
EBT
-2.36M-2.99M-3.48M-4.71M-4.94M-5.49M-4.90M-5.13M-5.33M-4.11M-3.30M-5.12M-2.18M-5.09M-12.09M-4.28M-4.57M-15.95M-17.55M-6.75M
Profit After TaxPAT
-2.33M-2.80M-3.47M-4.67M-4.29M-5.13M-4.82M-4.34M-5.30M-4.09M-3.33M-5.19M-2.32M-5.95M-12.09M-4.28M-4.86M-15.05M-17.79M-6.87M
Income from Continuing OperationsIncome (Continuing)
-2.36M-2.99M-3.48M-4.71M-4.94M-5.49M-4.90M-5.13M-5.33M-4.11M-3.30M-5.12M-2.18M-5.09M-12.09M-4.28M-4.57M-15.95M-17.55M-6.75M
Consolidated Net IncomeConsol Net Inc.
-2.36M-2.99M-3.48M-4.71M-4.94M-5.49M-4.90M-5.13M-5.33M-4.11M-3.30M-5.12M-2.18M-5.09M-12.09M-4.28M-4.57M-15.95M-17.55M-6.75M
Income towards Parent CompanyParent Net Inc
-2.36M-2.99M-3.48M-4.71M-4.94M-5.49M-4.90M-5.13M-5.33M-4.11M-3.30M-5.12M-2.18M-5.09M-12.09M-4.28M-4.57M-15.95M-17.55M-6.75M
Preferred Dividend PaymentsPref Dividends
1.73M0.12M
Net Income towards Common StockholdersNet Income
-2.36M-2.99M-3.48M-4.71M-4.94M-5.49M-4.90M-5.13M-5.33M-4.11M-3.33M-5.19M-2.32M-5.95M-12.09M-4.28M-4.86M-15.05M-19.51M-6.87M
Additional items
EPS (Basic)
-135.15-233.90-176.85-239.36-251.49-279.02-224.43-128.32-55.69-758.63-21.35-24.30-5.22-16.70-2.51-5.13-5.82-21.83-21.28-7.17
EPS (Diluted)
-135.15-233.90-176.85-239.36-251.49-279.02-224.43-128.32-55.69-758.63-21.35-24.30-8.55-16.70-2.51-5.13-5.82-21.83-21.28-7.17
Shares Outstanding
0.02M0.01M0.02M0.02M0.02M0.02M0.02M0.04M0.10M0.01M0.16M0.21M0.44M0.36M4.82M0.83M0.83M0.69M0.92M0.96M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
0.02M0.01M0.02M0.02M0.02M0.02M0.02M0.04M0.10M0.01M0.16M0.21M0.27M0.36M4.82M0.83M0.83M0.69M0.92M0.96M
EBITDA
-2.36M-2.99M-3.48M-4.71M-4.95M-5.50M-4.89M-5.12M-5.31M-4.10M-3.29M-5.11M-2.17M-5.09M-3.17M-4.22M-4.56M-16.03M-17.76M-6.79M
Interest ExpensesInt Expense
333.000.01M0.01M0.02M0.02M0.01M0.00M0.01M0.00M114.000.01M542.00